Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02

Opinion
Video

Experts discuss the factors supporting the choice of trastuzumab deruxtecan following disease progression and its mechanism of action in addressing resistance to prior HER2-targeted therapy and provide insights on the updated analysis from the DESTINY-Gastric02 Trial.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts in this video
4 experts in this video
Related Content